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Abstract 
In this review, we discuss the divergent role of the two closely related cytokine, interleukin (IL)-12 and 
IL-23, in shaping immune responses.  In light of current therapeutic developments using biologic agents 
to block these two pathways, a better understanding of the immunological function of these cytokines 
is pivotal. 
 
Introduction: 
The cytokines IL-12/23 are known to be pro-inflammatory and recognised to be involved in driving 
autoimmunity and inflammation.  Antibodies blocking IL-12/23 have now been developed to treat 
patients with chronic inflammatory conditions such as seronegative spondyloarthropathy, psoriasis, 
inflammatory bowel disease, as well as multiple sclerosis.  The anti-IL-12/23 drugs are very exciting 
for the clinician to study and use in these patient groups who have chronic, sometimes disabling 
conditions - either as a first line, or when other biologics such as anti-TNF therapies have 
failed.  However, IL-12/23 have important biological functions, and it is recognised that their presence 
drives the body’s response to bacterial and viral infections, as well as tumour control via their regulation 
of T cell function.  We can therefore be excited, but also need to be cautious about the use of biologic 
therapies that block them.  In the rare conditions, where there is a congenital deficit of IL-12/23, patients 
have presented with overwhelming infections.  In this review, we cover the science behind the biologic 
role of IL-12/23, the evidence for biologic therapies targeting them in the clinical situation, as well as 
mention cases in the literature when patients have been found to have primary IL-12/23 deficiency.   
  
IL-12/23 background 
 
IL-12 is a pro-inflammatory cytokine that induces T helper type 1 (Th1) differentiation in CD4 T cells 
and acts as a third signal in the activation of CD8 T cells. IL-12 is made up of two covalently linked 
subunits p35 and p40, which together form the active heterodimer p70. The p40 subunit is shared with 
IL-23, a cytokine driving the development of IL-17 producing CD4 T cells. The second subunit p19 is 
unique to IL-23. While IL-12 has been studied in some detail, IL-23 has only been discovered recently 
(1), and less is known about its specific functions. However, it is becoming clear that IL-12 and IL-23 
have distinct and often opposing functions. Biological activity and receptor binding is conferred by the 
shared p40 subunit. Both cytokines, IL-12 and IL-23 can be produced by activated dendritic cells and 
macrophages after sensing microbial products, however, expression of p35 and p19 is tightly regulated 
(2). IL-12 and IL-23 share a receptor chain, IL-12R-1, which then combines with IL-23R for IL-23 
signalling (2, 3) or IL-12R-2 for IL-12 signalling (2, 4) (Figure 1). 
 
Activation of T cells, the 3 signal hypothesis 
 
T cells are vital in combating infection and inhibiting cancer growth. In order to be fully activated 
cytotoxic CD8 T cells need 3 signals according to the 3 signal hypothesis (5) (comprehensively 
reviewed in Goral 2011). Signal 1 is provided by recognition of peptide loaded MHC molecule through 
the T cell receptor, signal 2 is provided by co-stimulation through interactions of molecules expressed 
on the antigen-presenting cell with those on the T cell (e.g. CD28 with CD80/86). Finally, signal 3 is 
provided by pro-inflammatory cytokines (Figure 2). The best described cytokines to provide signal 3 
are type I IFNs (IFN-) and IL-12 (5, 6). The IL-12 receptor is upregulated upon TCR stimulation on 
naïve T cells and expression is maintained on memory cells (7).  
When naïve cytotoxic T cells are primed in the absence of signal 3 they only develop weak effector 
functions, failing to proliferate extensively, survive long term and form adequate memory responses (5, 
8). T cell activation can be blocked through therapeutic intervention at each of the three signalling steps, 
(9). 
 
Immune function of IL-12 on T cells 
 
IL-12 regulates the expression of many genes important for effector T cell function, such as FasL and 
granzyme B. It also regulates the transcription factor T-bet, which in turn promotes IFN production 
(10) and stimulates Th1 responses in CD4 T cells. IL-12 stimulated CD8 T cells produce increased 
amounts of IFN, TNF and macrophage colony stimulating factor (GM-CSF) and show increased 
persistence and function in T cell adoptive therapies (11). Furthermore, adjuvants activate the immune 
system by inducing dendritic cells to produce inflammatory cytokines such as IL-12 (12). 
 
IL-12 counteracts T cell exhaustion 
 
Repetitive stimulation of T cells  for example by persistent antigens leads to a loss of effector functions, 
leading to a reduction in proliferation, cytotoxicity, cytokine production and ultimately viability, a 
process termed T cell exhaustion (13). Studies in patients with chronic hepatitis B and D have shown 
that T cell function was recovered by stimulation with IL-12 in culture (14, 15). These findings suggest 
that in chronic viral infections anti-viral T cells might benefit from IL-12 signalling.  
 
Memory cells can respond to IL-12 in the absence of T cell receptor signalling with cytokine production, 
thereby supporting or aggravating an ongoing immune response (16, 17).  
 
Additionally, IL-12 has also been described to have some regulatory properties in experimental 
autoimmune disease (18). Therefore, simultaneous blockade of IL-23/12 by p40 blocking agents (such 
as ustekinumab) might have disadvantages that need to be monitored closely to understand the 
pleiotropic effects of IL-12 signalling in vivo (19). 
 
Immune function of IL-23 on T cells 
 
In contrast to IL-12 signalling, naïve T cells cannot respond to IL-23, as they lack expression of the IL-
23R chain (2), while memory and effector CD4 T cells can express the IL-23 receptor. Its upregulation 
on activated T cells is stimulated by autocrine IL-21 in response to IL-6, produced by dendritic cells 
during inflammation. However, IL-21 deficient mice still expressed IL-23R, suggesting alternative 
pathways exist (2). IL-23 has been implicated in maintaining inflammatory responses and chiefly drives 
IL-17A and F production (inducing Th17 rather than Th1 CD4 cells) (2). In the absence of IL-23, IL-
17 producing cells can be induced by TGF- and IL-6, however, these cells failed to induce disease in 
an autoimmune model, possibly due to containing a subpopulation of cells co-producing IL-17 and the 
immune suppressive cytokine IL-10, which could confer regulatory function (20).  
It therefore seems that IL-23 is required for the pathogenic role of IL-17 producing T cells (21). So far, 
the effect of IL-23 has mainly been shown for CD4 effector memory cells and increased numbers of 
IL-23R+ CD4 T cells were shown to exist in autoimmune disease (AID). For example in synovial fluid 
up to 95% of CD4 T cells can be memory cells capable of responding to IL-23. The exact mechanism 
of action of IL-23 on CD8 T cells remains to be elucidated (22). 
 
Clinical consequences of IL-12 deficiency 
Valuable pathological inferences can be made from studying the clinical consequences of molecular 
defects in cytokine signalling. There are a number of case series in the literature, documenting patients 
with inherited defects in IL-12 signalling, many of which are in the context of consanguinity. The IL-
12 and IFNγ pathways are inextricably linked; patients who have defective IL-12 production also have 
impaired IFNγ production (23). Genetic defects have now been described at a number of points in the 
IL-12/IFNγ signalling cascade. Such patients tend to present in infancy with persistent mycobacterial 
(known as Mendelian susceptibility to mycobacterial disease) and non-typhi salmonella infections and 
have a poor prognosis. Mycobacterial infection is often by otherwise poorly pathogenic non-tuberculous 
organisms or follows BCG vaccination. Of note, these patients do not seem to be as affected by infection 
with extra-cellular bacteria or respiratory viruses. 
Genetic defects affecting the IL-12/IFN pathway can be classified as follows: mutations in the IL-12p40 
subunit, the IL-12R (β1 or β2 chains), the IFN-γR (chains 1 and 2) and the downstream signalling 
molecule STAT1.  
IL-12p40 deficiency 
There appears to be a wide variation in the clinical consequences of IL-12p40 deficiency, varying from 
localised BCG infection to overwhelming mycobacterial or salmonella infection (24). 
One report documents the case of a 3 year-old female with recurrent episodes of severe staphylococcal 
and pneumococcal sepsis whose peripheral blood mononuclear cells (PBMCs) failed to produce IL-12 
despite appropriate stimulation (25). It was thought that the patient had either an abnormality in the 
activation pathway for IL-12 p40 gene expression or an abnormality in the gene itself. In another IL-12 
p40-deficient child, disseminated salmonella and BCG infection were curable with chemotherapy and 
IFN-γ supplementation (26). The father of this child was heterozygous for this defect and had persistent 
non-typhi salmonella infection in infancy, eventually cured with prolonged antibiotics. Since p40 is the 
shared subunit, these patients would have also been IL-23 deficient, but the influence of this cytokine 
has not been studied in these cases (?). 
IL-12R deficiency  
The IL-12Rβ1 chain is common to both the IL-12 and IL-23 receptors and thus deficiency abolishes 
signalling of both Il-12 and IL-23. IL-12Rβ1 deficiency is inherited in an autosomal recessive fashion 
and is caused by mutations resulting in premature stop codons (27). Heterozygous carriers appear to be 
clinically healthy with normal IL-12 signalling and IFNγ production.  
Fieschi et al (2003) conducted a comprehensive review of IL-12Rβ1- deficient patients and found that 
there was a surprising heterogeneity in terms of clinical outcome; furthermore, there was also evidence 
of incomplete clinical penetrance as homozygous individuals identified through family screening had 
remained asymptomatic up to age 18 years (28). 
The clinical course of infection in IL-12Rβ1 deficiency is variable. Two such patients who developed 
disseminated BCGosis were successfully treated with antituberculous chemotherapy; three further 
patients had curable M. Avium infection (29). In another family affected by IL-12Rβ1 deficiency, 
however, one child died of disseminated M. Avium despite chemotherapy, while his brother was cured 
by the addition of IFNγ (29).  
A further patient has been described who developed disseminated BCGosis aged 4 months who was 
found to have a homozygous mutation of the IL-12β1 gene leading to absent IL-12β1 expression on 
activated T cells. The patient relapsed after initial successful chemotherapy aged 3 years. During futher 
antimycobacterial treatment he developed cutaneous leukocytoclastic vasculitis later shown to be 
secondary to infection with salmonella enteriditis (30). 
Another report documents an 8-year old girl with recurrent bronchopneumonia (due to Haemophilus on 
one occasion) associated with very high IgE levels (31). She was found to have a complete absence of 
the IL-12Rβ2 chain due to a novel mutation. The patient’s family history was notable for a high 
incidence of atopy in both lineages. This supports the theoretical notion that an impairment in type-1 
immunity might upregulate the Th2-associated cytokines (IL-4, IL-5 and IL-13) which mediate allergic 
responses.  
 
ROLE OF IL-12/23 IN CHRONIC INFLAMMATION 
 
The ability of IL-12 to induce the differentiation of naïve T cells into IFN-γ-producing Th1 cells, and 
that of IL-23 to drive the expansion of IL-17-producing T-cell population, are suggestive of IL-12 and 
23 involvement in autoimmunity and chronic inflammation. Animal model studies identified that mice 
deficient in the expression of p40 subunit of IL-12/23 were protected from developing arthritis, ocular 
or bowel inflammatory conditions after immunisation with specific antigens (32, 33). However, it is 
very likely that IL-12 and 23 also have divergent immune functions, as it was subsequently found that 
mice lacking IL-12 (p35) were highly susceptible to experimental autoimmune encephalomyelitis 
(EAE), whereas IL-12/23p40-deficient mice were completely resistant to developing this pathology 
(34). Further studies, showing the equivalence of two mice phenotypes (lacking the IL23p19 or IL-
12/23p40 subunits), suggested that IL-23, rather than IL-12, is the major orchestrator of autoimmunity 
(35).    
In addition to animal models, the presence of these two cytokines at the site of autoimmune 
inflammation in various human pathology provided additional rationale for their use as therapeutic 
targets.   
Psoriasis and psoriatic arthritis (PsA) 
The role of IL-12/23 in driving the excessive growth and aberrant differentiation of keratinocytes in 
psoriasis was proven by biopsy studies, which found high concentrations of IL-12/23p40, as well as IL-
23p19 mRNA in psoriatic skin lesions compared to normal skin (36). In addition, IFN-γ, IL-17A, IL-
17F and IL-22 were overexpressed in psoriasis plaques (37). However, in contrast to IL-23 that triggered 
abnormal differentiation of keratinocytes, IL-12 did not cause similar skin changes, suggesting a 
possible differential effect of the two cytokines (38). 
The susceptibility to develop PsA was associated with single-nucleotide polymorphisms (SNPs) within 
IL-23R and IL-12B, the gene that encodes for subunit of ligand of IL-23R (39). Increased frequencies 
of IL-17 and IL-22 producing and IL23R expressing CD4+ T cells were also found in patients with PsA 
(40).  
Inflammatory bowel disease (IBD) 
There is evidence of elevated expression of the IL-12/23 p40 subunit both at mRNA and protein levels 
in bowel biopsies and serum in patients with IBD, and more significantly in patients with Crohn’s 
disease (CD) (41). In addition, IL-12 Rβ2 had increased expression in CD biopsies and was upregulated 
by increased concentration of IL-12, and correlated with the activity of STAT4 proteins and IFN-γ 
expression (42). Moreover, the IL-12 polymorphisms were associated with both CD and ulcerative 
colitis (UC) susceptibility (43, 44). Furthermore, inhibition of IL-12/23 p40 subunit repressed Th1 
immune responses, immune cell proliferation and promoted apoptosis in a mouse model of experimental 
colitis (45). All these biologic effects supported the hypothesis of therapeutic benefits associated with 
IL-12 inhibition in IBD.  
 
IL-23 responsive innate lymphoid cells were identified in higher proportion in the bowel biopsies of 
patients with IBD (46). In addition, IL-23 was implicated in mucosal inflammation mediated by p19 
subunit, whereas in the absence of IL-23, mice developed enhanced IL-12–driven inflammation (47). 
This suggested a potential mechanism of cross-regulation of both cytokines that might be relevant for 
therapeutic purposes.  
 
 
 
Multiple sclerosis (MS) 
 
IL-23 played a key role in perpetuating the immune responses in an animal model of EAE, as the IL-
12/23p40 subunit expression by CNS-endogenous cells was critical for the development of the 
autoimmune inflammatory process (48). 
 
THERAPEUTIC EFFECTS OF IL-12/23 BLOCKADE 
There are several biologic agents targeting IL-12/23 and IL-23 inhibition that are currently under 
development or used in practice (Table 1). We detail below the most researched biologic treatments. 
Figure 3 details the differential blockade of the available biologic therapies. 
IL-12/23 blockage in psoriasis and PsA 
Ustekinumab (a human monoclonal targeting the IL-12/23 p40) is currently licensed for use in psoriasis 
based on the successful outcome of two large phase III randomised controled trials (RCTs) (49, 50). 
Ustekinumab is administered as subcutaneous injection of 45 mg or 90 mg at week 0, week 4, and every 
12 weeks afterwards.  
Briakinumab, another monoclonal antibody with similar target, was also effective in treating psoriasis 
(administered subcutaneously as monthly 200 mg injections for the first two doses, followed by 100 mg 
thereafter). However, this treatment was associated with a higher incidence of major adverse cardiac 
events (MACE), such as myocardial infarction, stroke or cardiovascular death, which led to the 
withdrawal of its registration application until further analysis or future studies become available (51). 
The efficacy of Ustekinumab in treating moderate to severe PsA was confirmed in two large phase III 
clinical trials (52, 53). In addition to providing benefits in controlling the symptoms of arthritis, 
ustekinumab was also effective in improving enthesitis, and spinal inflammation. Despite not reaching 
statistical significance, IL-12/23 inhibition was also associated with clinical benefits in the treatment of 
dactylitis (54).  
Future development of IL12/23 blockade in psoriasis and PsA 
Despite the incontestable benefits of ustekinumab treatment in PsA and psoriasis, recent research 
suggested that the development of selective IL-23 blockage might have a theoretical advantage over IL-
12 inhibition, as the inhibition of radiographic progression seems to be linked to the IL-23 - Th17 - IL-
17 pathway of osteoclast activation (55). In addition, IL-23 deficient mouse model was protected against 
developing arthritis, while IL-12 deficient mouse model developed severe synovitis (32), suggesting 
that IL-23 is the major contributor to PsA. 
IL-12/23 blockage in rheumatoid arthritis 
Phase II clinical trials of ustekinumab and guselkumab in RA did not meet their primary endpoint, and 
the clinical research program was discontinued. 
 
IL-12/23 blockage in IBD 
Ustekinumab is also effective in treating autoimmune inflammation associated with CD, irrespective of 
prior exposure to anti TNF therapy (56, 57).  UNITI-1 [ClinicalTrials.gov identifier: NCT01369329] 
and UNITI-2 [ClinicalTrials.gov identifier: NCT01369342] are two large phase III RCTs in patients 
with CD, which are expected to be completed in November 2018. There is a suggestion that IL-12/23 
inhibition might be more suitable in patients with late CD, as they had an increase in the peripheral 
Th17 cells and related cytokines, compared to patients with early disease (58). Briakinumab program 
in CD (NCT00562887) was terminated, as the primary endpoint of clinical remission at week 6 was not 
met in a phase II RCT (59).  
Another anti IL-12/23 p40 subunit monoclonal antibody (ABT-874/J695) was also tested in a phase II 
RCT in patients with CD. The treatment was associated with a significant improvement of bowel 
inflammation after 7 weeks of uninterrupted administration at a dose of 3 mg/kg, but this response was 
not maintained at week 18 (primary endpoint). In the responder group, the treatment was associated 
with decrease in the Th1-mediated inflammatory cytokines in the colonic lamina propria (60). Because 
the study did not meet the primary endpoint, the research program was discontinued. 
IL-12/23 blockage in MS 
There is evidence of some benefit associated with treatment with briakinumab in relapsing-remitting 
multiple sclerosis (RRMS), consisting either in lower relapse rate at week 23 or decreased number of 
gadolinium-enhanced lesions on MRI, but the benefit was not significant enough to grant further 
development in MS. In contrast, ustekinumab was no associated with clinical benefit or imaging 
improvement in MS (61). 
IL-12/23 blockage relevance for tumour growth 
There is evidence of opposing effects of IL-12 and IL-23 inhibition effect on tumour overgrowth, which 
is relevant for the equilibrium phase of cancer immunoediting (62), as well as for the potential risk of 
cancer in patients treated with ustekinumab for other indications. While, the IL-23 blockage in a 
sarcoma mouse model eliminated the residual tumour cells, the inhibition of both IL-12 and 23 (using 
an IL-12/23p40 neutralization antibody) enabled the progression of tumours (63). Further research 
aiming to establish the therapeutic role of these dual biologic inhibitory agents in cancer is required.  
Table 1: Available biologic therapies for IL-12 and IL-23 blockage (as updated from 
https://clinicaltrials.gov/ct2/- August 2016). 
    Therapeutic 
agents 
Diseases 
IL-12/23p40 blockade IL-23p19 blockade 
Ustekinumab Briakinumab Guselkumab Tildrakizumab AMG-
139 
LY-
3074828 
BI-
655066 
Psoriatic 
arthritis 
Licensed for 
use 
Phase II Phase II    Phase II 
Psoriasis Licensed for 
use 
Phase II* Phase III Phase III Phase I Phase I Phase III 
Ankylosing 
Spondylitis 
Phase III Phase II    Phase I Phase II 
Rheumatoid 
Arthritis 
Phase II 
(ineffective) 
 Phase II 
(ineffective) 
    
Crohn’s 
disease** 
Phase III Phase II 
(Ineffective) 
  Phase I  Phase II 
Ulcerative 
colitis 
     Phase II  
Multiple 
sclerosis 
Phase II 
(Ineffective) 
Phase II*      
 *Program discontinued in 2011 
** The research program of ABT-874/J695 (another IL12p40 blocking agent) was discontinued 
in 2005. 
 
Side-effects to IL-12/23 blockage 
The combined analysis of phase II and III RCTs in psoriasis revealed a similar rate of adverse-events 
per 100 patient years in the ustekinumab treated groups compared with placebo (64). A meta-analysis 
of the phase II and III trials of briakinumab identified cases of opportunistic infections (Candida) (65), 
but there was no evidence of mycobacterial or Salmonella infections secondary to treatment with either 
ustekinumab or briakinumab. There are a few case reports of acute and re-activation of HBV infection 
(66, 67); however, the expert opinion is that the risk of chronic viral infection associated with the use 
of ustekinumab is very low (68). The rate of MACE, opportunistic infections and malignancy (non-
melanoma skin cancers were the most common) was higher in the patients treated with briakinumab 
compared to ustekinumab. This could be explained by the more frequent dosing schedule of 
briakinumab and its higher affinity to IL-12/23 p40, both leading to higher drug exposure (49, 69). 
Ustekinumab is the only IL-12/23 inhibitor licensed for use in moderate-severe psoriasis (since 2009) 
and psoriatic arthritis (since 2013). An application was recently made seeking approval for use of 
ustekinumab in CD.  
Discussion: 
Although, there is strong evidence for the contribution of IL-12 and 23 to autoimmunity and successful 
blockade of these cytokines in clinical practice, questions remain about the long-term efficacy of this 
therapeutic intervention and differential roles of IL-12 and 23.  
Case reports of IL-12 deficiencies are characterised by increased risk of infections (especially 
mycobacterial disease) from early age, suggesting that a complete blockade of both cytokines could be 
associated with significant toxicity; however, there are no significant side effects documented from 
clinical trials of ustekinumab. In comparison, briakinumab, characterised by greater binding affinity 
and used at a higher equivalent dose in clinical trials, generated significant safety concerns, which 
prompted the discontinuation of its research program.  
Although the neutralisation or absence of IL-23 in a murine model did not compromise the immune 
response to mycobacteria (70), humans with IL-23 deficiency are prone to low-virulence mycobacterial 
infections and nontyphoid salmonella infections (71). Interestingly, in a murine model, the presence of 
IL-23 can compensate partially for the absence of IL-12, which indicates a degree of immune 
redundancy characterising the function of the two cytokines (70).  
Even if there are only a few cases of hepatitis B reactivation secondary to IL-12/23 blockade reported 
in the literature, there is evidence suggesting that IL-12 blockage might impair the immune system 
capacity to tackle hepatitis infection. In vitro stimulated human CD8 T cells from patients with chronic 
hepatitis B showed decreased PD-1 expression and survived better in the presence of IL-12 than IFNα; 
and IL-12 led to an induction of the transcription factor Tbet (14). In line with these findings, increased 
Tbet expression in murine T cells (LCMV) and human T cells in chronic hepatitis C, correlated with 
improved cell survival and function (72). As the majority of patients in clinical trials are screened for 
chronic hepatitis and excluded if tested positive, and there is a potential bias in reporting adverse events 
outside clinical trials, only the future will tell if these new biologic agents are associated with increased 
hepatitis infection/reactivation risk.  
In addition, the differential effect of IL-12 and 23 in tumorigenesis control in animal models could raise 
questions about the optimal IL-12/23 blockage ratio needed to minimise the risk of cancer potentially 
associated with this therapy. If IL-12 blockage enabled tumour progression in a murine cancer model, 
IL-12 stimulated T cells were significantly more effective in controlling tumours than IFNα stimulated 
cells, and showed a lower expression of the co-inhibitory receptor PD-1 (73). 
Apart from the problem of long-term safety, further research is needed to elucidate the most effective 
strategy to block selectively IL-12, IL-23 or both for different therapeutic purposes.  P40 and p19 
deficient mice are both resistant to EAE. However, p35 deficient mice show increased susceptibility to 
EAE (2), implying that IL-12 is not driving this autoimmune process. Deficiency of IL-12R1 chain 
also made mice resistant to EAE. Despite these findings suggesting that IL-23 blockade might be 
beneficial in MS, ustekinumab was not associated with clinical improvement; however, briakinumab, 
despite sharing the same target, was effective (probably because of its higher binding affinity). Further 
research into selective IL-23 blockade might identify successful therapeutic strategies for MS. 
Different effects of IL-12 and IL-23 were identified in CD as well. While systemic inflammation was 
driven by IL-23 p35 secretion, the intestinal inflammation was associated with IL-23 p19 and IL-17A 
mRNA, suggesting a differential role of IL-23 in the mucosal inflammation and potential benefit of 
selective IL-23 blockage (33, 74). Similarly, it was advocated that IL-23 inhibition in PsA is likely to 
be clinically more relevant than IL-12 inhibition, because of the effect of this pro-inflammatory cytokine 
on the Th17/ IL-17 pathway activation, which is relevant for the development of bone erosions.   
In conclusion, further research into the mechanism of action of different IL-12/23 blocking agents is 
needed to characterize better the impact of these therapies on the homeostasis of the immune system 
and organ-specific inflammation associated with various autoimmune diseases.  Long-term clinical data 
will further delineate if the increased infection risk characterising human IL12/23 immunodeficiency 
syndromes and the impaired tumorigenesis control identified in animal models will translate in relevant 
clinical events. Although it is likely that the IL-23 rather than IL-12 blockade might be more relevant 
for autoimmunity, head-to-head studies looking at the available biologic agents that selectively block 
the two cytokines are required for successfully translating this therapeutic strategy in clinical practice.   
 
Key messages: 
1. Biologic treatments targeting IL-12/23 blockade are effective in controlling the inflammation 
associated with several autoimmune diseases 
2. Congenital IL-12 immunodeficiency has been described as associated with severe bacterial 
infections 
3. Despite re-assuring toxicity profile of therapeutic IL-12/23 inhibition, clinicians should be 
aware of potential long-term infective complications associated with these new biologic agents  
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